---
title: "CSPC PHARMA SYH 9089 injection approved for clinical use in China"
description: "CSPC PHARMA announced that the long-acting injection of ropivacaine (SYH 9089 injection) developed by the group has been approved by the National Medical Products Administration and can conduct clinic"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276035823.md"
published_at: "2026-02-16T06:09:51.000Z"
---

# CSPC PHARMA SYH 9089 injection approved for clinical use in China

> CSPC PHARMA announced that the long-acting injection of ropivacaine (SYH 9089 injection) developed by the group has been approved by the National Medical Products Administration and can conduct clinical trials in China. The group stated that through its long-acting drug delivery technology platform, this product can extend the duration of analgesia from a single dose to one week, and is expected to become China's first ultra-long-acting analgesic product with a duration of one week

CSPC PHARMA (01093.HK) announced that the long-acting injection of ropivacaine (SYH 9089 injection) developed by the group has been approved by the National Medical Products Administration and can conduct clinical trials in China.

The group stated that through its long-acting drug delivery technology platform, this product can extend the duration of analgesia from a single dose to one week, and is expected to become China's first ultra-long-acting analgesic product with a duration of one week

### Related Stocks

- [01093.HK - CSPC PHARMA](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/en/news/276056763.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/en/news/276035104.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/en/news/276051793.md) |
| Hangzhou Jiuyuan Gene Engineering IND Application for JY54 Injection Accepted by CDE | Hangzhou Jiuyuan Gene Engineering Co. Ltd. has announced that its IND application for JY54 Injection has been accepted b | [Link](https://longbridge.com/en/news/275289286.md) |
| CSPC Pharma Gets China Nod for Multiple Drug Trials | CSPC Pharma Gets China Nod for Multiple Drug Trials | [Link](https://longbridge.com/en/news/270994613.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.